Improved treatment strategies can result in better outcomes following one-stage exchange surgery for MRSA periprosthetic joint infection
Standard
Improved treatment strategies can result in better outcomes following one-stage exchange surgery for MRSA periprosthetic joint infection. / Ohlmeier, Malte; Filitarin, Sergei; Delgado, Giorgio; Frings, Jannik; Abdelaziz, Hussein; Salber, Jochen; Frommelt, Lars; Gehrke, Thorsten; Citak, Mustafa.
In: J MED MICROBIOL, Vol. 69, No. 8, 08.2020, p. 1100-1104.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Improved treatment strategies can result in better outcomes following one-stage exchange surgery for MRSA periprosthetic joint infection
AU - Ohlmeier, Malte
AU - Filitarin, Sergei
AU - Delgado, Giorgio
AU - Frings, Jannik
AU - Abdelaziz, Hussein
AU - Salber, Jochen
AU - Frommelt, Lars
AU - Gehrke, Thorsten
AU - Citak, Mustafa
PY - 2020/8
Y1 - 2020/8
N2 - Introduction. Periprosthetic joint infections caused by methicillin-resistant Staphylococcus aureus (MRSA-PJIs) are rare, with only a few studies reporting the treatment outcomes and even fewer reporting outcomes with one-stage exchange.Aim. This study aims to analyse the outcomes of one-stage exchange in the management of MRSA-PJIs.Methodology. Patients with MRSA-PJI of the hip and knee, who were treated with a one-stage exchange between 2001 and 2018 were enrolled in this study. The final cohort comprised of 29 patients, which included 23 hips and six knees. The mean follow-up was 5.3 years (1-9 years). Reinfection and complications rates after the one-stage exchange were analysed.Results. Overall infection control could be achieved in 93.1 % (27 out of 29 patients). The overall revision rate was 31.0% (9 patients), with three patients requiring an in-hospital revision (10.3 %). Six patients had to be revised after hospital discharge (20.7 %). Of the two reinfections, one had a growth of MRSA while the other was of methicillin-sensitive Staphyloccocus epidermidis.Conclusion. One-stage exchange surgery using current techniques could improve surgical outcomes with excellent results in the management of MRSA-PJIs.
AB - Introduction. Periprosthetic joint infections caused by methicillin-resistant Staphylococcus aureus (MRSA-PJIs) are rare, with only a few studies reporting the treatment outcomes and even fewer reporting outcomes with one-stage exchange.Aim. This study aims to analyse the outcomes of one-stage exchange in the management of MRSA-PJIs.Methodology. Patients with MRSA-PJI of the hip and knee, who were treated with a one-stage exchange between 2001 and 2018 were enrolled in this study. The final cohort comprised of 29 patients, which included 23 hips and six knees. The mean follow-up was 5.3 years (1-9 years). Reinfection and complications rates after the one-stage exchange were analysed.Results. Overall infection control could be achieved in 93.1 % (27 out of 29 patients). The overall revision rate was 31.0% (9 patients), with three patients requiring an in-hospital revision (10.3 %). Six patients had to be revised after hospital discharge (20.7 %). Of the two reinfections, one had a growth of MRSA while the other was of methicillin-sensitive Staphyloccocus epidermidis.Conclusion. One-stage exchange surgery using current techniques could improve surgical outcomes with excellent results in the management of MRSA-PJIs.
KW - Adult
KW - Aftercare
KW - Aged
KW - Aged, 80 and over
KW - Anti-Bacterial Agents/administration & dosage
KW - Arthritis, Infectious/surgery
KW - Cohort Studies
KW - Debridement
KW - Female
KW - Hip Prosthesis/adverse effects
KW - Humans
KW - Knee Prosthesis/adverse effects
KW - Male
KW - Methicillin-Resistant Staphylococcus aureus
KW - Middle Aged
KW - Prosthesis-Related Infections/surgery
KW - Recurrence
KW - Reoperation
KW - Retrospective Studies
KW - Staphylococcal Infections/surgery
KW - Time Factors
KW - Treatment Outcome
U2 - 10.1099/jmm.0.001229
DO - 10.1099/jmm.0.001229
M3 - SCORING: Journal article
C2 - 32639225
VL - 69
SP - 1100
EP - 1104
JO - J MED MICROBIOL
JF - J MED MICROBIOL
SN - 0022-2615
IS - 8
ER -